DeepMed Research

MEDIWOUND LTD

🇮🇱Israel

Country: 🇮🇱Israel

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Clinical Study to Evaluate the Safety and the Efficacy of EscharEx Drug Product (EX-03 Formulation) and Its Placebo Compared to Collagenase, Non-surgical Standard of Care, in Patients With Venous Leg Ulcers

Phase 2

Not yet recruiting

Conditions: Venus Leg Ulcers

Interventions: Drug: EscharEx (EX-03)
Drug: Placebo (Gel vehicle)

First Posted Date: 2024-11-15

Last Posted Date: 2024-11-15

Lead Sponsor: MediWound Ltd

Target Recruit Count: 45

Registration Number: NCT06690177

Locations: 🇺🇸
ILD Research Center, Carlsbad, California, United States
🇵🇱
Wojskowy Instytut Medyczny, Warsaw, Poland

A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)

Phase 3

Recruiting

Conditions: Venous Leg Ulcer (VLU)

Interventions: Drug: EscharEx (EX-03)
Drug: Placebo (Gel vehicle)

First Posted Date: 2024-08-23

Last Posted Date: 2025-04-24

Lead Sponsor: MediWound Ltd

Target Recruit Count: 216

Registration Number: NCT06568627

Locations: 🇺🇸
Limb Preservation Platform, Inc, Fresno, California, United States
🇺🇸
Center for Clinical Research INC, San Francisco, California, United States
🇺🇸
Northwell Health Comprehensive Wound Healing Center, Lake Success, New York, United States

and more 2 locations

A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma

Phase 1

Conditions: Nodular Basal Cell Carcinoma
Superficial Basal Cell Carcinoma

Interventions: Drug: EscharEx 5% (EX-02 formulation)

First Posted Date: 2021-12-15

Last Posted Date: 2021-12-15

Lead Sponsor: MediWound Ltd

Target Recruit Count: 32

Registration Number: NCT05157763

Locations: 🇺🇸
Center for Clinical and Cosmetic Research, Aventura, Florida, United States
🇺🇸
Moore Clinical Research, Inc., Brandon, Florida, United States
🇺🇸
Center for Clinical Studies, LTD. LLP, Webster, Texas, United States

A Study to Evaluate the Clinical Performance, Safety and Pharmacology Effect of EscharEx in Patients With Lower Leg Ulcers

Phase 2

Completed

Conditions: Venous Leg Ulcer
Diabetic Foot Ulcer

Interventions: Drug: EscharEx (EX-02 formulation)

First Posted Date: 2021-03-26

Last Posted Date: 2022-07-26

Lead Sponsor: MediWound Ltd

Target Recruit Count: 12

Registration Number: NCT04817228

Locations: 🇺🇸
Clinical Research Medical Center, LLC, Las Vegas, Nevada, United States
🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸
Barry University foot and ankle institute, Tamarac, Florida, United States

Use of NexoBrid for Treatment of Acute Deep Partial and Full Thickness Burn Injuries

Conditions: Thermal Burn

First Posted Date: 2019-08-01

Last Posted Date: 2024-08-30

Lead Sponsor: MediWound Ltd

Registration Number: NCT04040660

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Bridgeport Hospital, Bridgeport, Connecticut, United States
🇺🇸
Stony Brook University Medical Center, Stony Brook, New York, United States

and more 25 locations

A Study to Evaluate the Safety and the Efficacy of EscharEx (EX-02 Formulation) in Debridement of Venous Leg Ulcers

Phase 2

Completed

Conditions: Venous Leg Ulcer

Interventions: Drug: EscharEx (5% EX-02 formulation)
Drug: Gel Vehicle
Drug: Non-surgical standard of care (NSSOC)

First Posted Date: 2018-07-17

Last Posted Date: 2022-11-14

Lead Sponsor: MediWound Ltd

Target Recruit Count: 120

Registration Number: NCT03588130

Locations: 🇺🇸
ILD Research Center, Carlsbad, California, United States
🇺🇸
Stanford, Redwood City, California, United States
🇺🇸
Limb Preservation Platform, Inc., Fresno, California, United States

and more 19 locations

A Study to Evaluate the Efficacy and Safety of NexoBrid in Children With Thermal Burns Compared the Standard of Care

Phase 3

Conditions: Thermal Burns

Interventions: Drug: NexoBrid
Procedure: Standard of Care

First Posted Date: 2014-10-30

Last Posted Date: 2022-07-27

Lead Sponsor: MediWound Ltd

Target Recruit Count: 145

Registration Number: NCT02278718

Locations: 🇵🇱
Uniwersytecki Szpital Dzieciecy w Krakowie, Kraków, Poland
🇺🇸
Shriners Hospital for Children, Boston, Massachusetts, United States
🇺🇸
Drexel University, Philadelphia, Pennsylvania, United States

and more 33 locations

A Study to Evaluate the Efficacy and Safety of NexoBrid in Subjects With Thermal Burns

Phase 3

Completed

Conditions: Thermal Burns

Interventions: Drug: Gel Vehicle
Drug: NexoBrid
Procedure: Standard of Care (SOC)

First Posted Date: 2014-05-28

Last Posted Date: 2024-07-10

Lead Sponsor: MediWound Ltd

Target Recruit Count: 175

Registration Number: NCT02148705

Locations: 🇺🇸
University of Texas Medical Branch, Galveston, Texas, United States
🇺🇸
The General Hospital Corporation d/b/a Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
HarborView Medical Center, Seattle, Washington, United States

and more 26 locations

Efficacy and Safety Study of EscharEx to Treat (Debride) Hard to Heal Wounds

Phase 2

Completed

Conditions: Hard to Heal Wounds
Venous Leg Ulcers
Diabetic Lower Extremity Ulcers
Traumatic/ Post Operative Wounds

Interventions: Drug: EscharEx
Drug: Gel Vehicle

First Posted Date: 2013-12-25

Last Posted Date: 2018-08-31

Lead Sponsor: MediWound Ltd

Target Recruit Count: 111

Registration Number: NCT02020746

Locations: 🇮🇱
HaSharon hospital, Rabin MC, Petah Tikva, Israel
🇮🇱
Sheba MC, Ramat Gan, Israel
🇮🇱
Rambam MC - Plastic surgery ward, Haifa, Israel

and more 5 locations

Functionality Assessments in Patients (Adults and Children) Following Treatment With Debrase Compared to Standard of Care

Conditions: Burns, Upper Extremity
Burns, Lower Extremity

First Posted Date: 2013-02-28

Last Posted Date: 2013-02-28

Lead Sponsor: MediWound Ltd

Target Recruit Count: 53

Registration Number: NCT01800981

Locations: 🇸🇰
Clinic of Burns and reconstructive surgery hospital, Kosice, Slovakia

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy